Post-transplant lymphoproliferative disorder after liver transplantation: Incidence, long-term survival and impact of serum tacrolimus level

Table 3 Kaplan-Meier analysis of risk factors and post-transplant lymphoproliferative disorder survival of pediatric patients

	Mean survival in mo	P value
Sex		0.749
Male	41.41 ± 7.38
Female	35.85 ± 5.76
Multi-organ involvement		0.002
(+)	25.82 ± 6.90
(-)	67.62 ± 5.56
CMV status		0.139
CMV-positive	58.82 ± 9.56
CMV-negative	19.35 ± 6.21
EBV status		0.002
EBV-positive	60.58 ± 7.62
EBV-negative	5.58 ± 2.72
Rejection episode		0.888
(+)	43.61 ± 8.49
(-)	36.02 ± 5.24
Time to PTLD development in years		0.326
≤ 1	39.72 ± 6.86
≥ 1	36.45 ± 5.30
Type of allograft		0.806
Living donor	50.56 ± 6.95
Deceased donor	37.37 ± 8.11

CMV: Cytomegalovirus; EBV: Epstein-Barr virus; PTLD: Post-transplant lymphoproliferative disorder.